CD9 and glioblastoma: As we observed strong correlation between CD9 expression and expression of known stem-cell markers in the CD9-silenced GSCs, the worse prognosis for patients with GBM that shows higher CD9 expression might be explained by GBM resistance to therapy, possibly due to a higher fraction of GSCs [10].